Cadrenal Therapeutics, Inc. Common Stock Financial Flexibility Index
Cadrenal Therapeutics, Inc. Common Stock financial flexibility index. Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a Financial Flexibility Index of -2.82x as of March 2026. Free cash flow of $-3.00 Million (operating CF $-3.00 Million minus capex $3.00) represents -3% of total liabilities ($1.06 Million). See Cadrenal Therapeutics, Inc. Common Stock free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Cadrenal Therapeutics, Inc. Common Stock (2022–2025)
Financial flexibility index of Cadrenal Therapeutics, Inc. Common Stock from 2022 to 2025. Historical Financial Flexibility Index trend for Cadrenal Therapeutics, Inc. Common Stock across 4 annual periods. Explore cash flow to debt ratio of Cadrenal Therapeutics, Inc. Common Stock to assess how comfortably operating cash covers total debt obligations.
Cadrenal Therapeutics, Inc. Common Stock Financial Flexibility Index by Year (2022–2025)
Cadrenal Therapeutics, Inc. Common Stock financial flexibility index by year from 2022 to 2025. Year-by-year free cash flow to debt coverage for Cadrenal Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see cash flow conversion of Cadrenal Therapeutics, Inc. Common Stock.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -7.93x | $-12.60 Million | $-12.60 Million | $1.59 Million | ▼ -189.6% |
| 2024 | -2.74x | $-7.35 Million | $-7.36 Million | $2.68 Million | ▲ +35.8% |
| 2023 | -4.27x | $-3.53 Million | $-3.53 Million | $826.88K | ▼ -2145.6% |
| 2022 | -0.19x | $-1.20 Million | $-1.20 Million | $6.33 Million | — |